Home > Publications database > Exploring Structural and Molecular Features of Sciatic Nerve Lesions in Diabetic Neuropathy: Unveiling Pathogenic Pathways and Targets. > print

001     294070
005     20250210095351.0
024 7 _ |a 10.2337/db24-0493
|2 doi
024 7 _ |a pmid:39418320
|2 pmid
024 7 _ |a 0012-1797
|2 ISSN
024 7 _ |a 1939-327X
|2 ISSN
024 7 _ |a altmetric:169447111
|2 altmetric
037 _ _ |a DKFZ-2024-02091
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schwarz, Daniel
|b 0
245 _ _ |a Exploring Structural and Molecular Features of Sciatic Nerve Lesions in Diabetic Neuropathy: Unveiling Pathogenic Pathways and Targets.
260 _ _ |a Alexandria, Va
|c 2025
|b Assoc.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1739177610_13025
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Jan 1;74(1):65-74
520 _ _ |a Lesioned fascicles (LF) in the sciatic nerves of individuals with diabetic neuropathy (DN) correlate with clinical symptom severity. This study aimed to characterize the structural and molecular composition of these lesions to better understand DN pathogenesis. Sciatic nerves from amputees with and without type 2 diabetes (T2D) were examined using ex vivo magnetic resonance neurography, in vitro imaging, and proteomic analysis. Lesions were only found in T2D donors and exhibited significant structural abnormalities, including axonal degeneration, demyelination, and impaired blood nerve barrier (BNB). While non-lesioned fascicles from T2D donors showed activation of neuroprotective pathways, lesioned fascicles lacked this response and instead displayed increased complement activation via the classical pathway. The detection of liver-derived acute-phase proteins suggests that BNB disruption facilitates harmful inter-organ communication between the liver and nerves. These findings reveal key molecular mechanisms contributing to DN and highlight potential targets for therapeutic intervention.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Marois, Maxime Le
|b 1
700 1 _ |a Sturm, Volker
|b 2
700 1 _ |a Peters, Andreas S
|b 3
700 1 _ |a Longuespée, Rémi
|0 P:(DE-He78)69f4086396e9a4830b9bdb751b68f2a6
|b 4
|u dkfz
700 1 _ |a Helm, Dominic
|0 P:(DE-He78)daaed5a5b968028e6e95d273150d5ab1
|b 5
|u dkfz
700 1 _ |a Schneider, Martin
|0 P:(DE-He78)0d37cc734b95fed555f2244d6fee6320
|b 6
|u dkfz
700 1 _ |a Eichmüller, Bastian
|b 7
700 1 _ |a Hidmark, Asa S
|b 8
700 1 _ |a Fischer, Manuel
|b 9
700 1 _ |a Kender, Zoltan
|b 10
700 1 _ |a Schwab, Constantin
|b 11
700 1 _ |a Hausser, Ingrid
|b 12
700 1 _ |a Weis, Joachim
|b 13
700 1 _ |a Dihlmann, Susanna
|b 14
700 1 _ |a Böckler, Dittmar
|b 15
700 1 _ |a Bendszus, Martin
|b 16
700 1 _ |a Heiland, Sabine
|b 17
700 1 _ |a Herzig, Stephan
|b 18
700 1 _ |a Nawroth, Peter P
|b 19
700 1 _ |a Szendroedi, Julia
|b 20
700 1 _ |a Fleming, Thomas
|b 21
773 _ _ |a 10.2337/db24-0493
|g p. db240493
|0 PERI:(DE-600)1501252-9
|n 1
|p 65-74
|t Diabetes
|v 74
|y 2025
|x 0012-1797
909 C O |p VDB
|o oai:inrepo02.dkfz.de:294070
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)69f4086396e9a4830b9bdb751b68f2a6
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)daaed5a5b968028e6e95d273150d5ab1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)0d37cc734b95fed555f2244d6fee6320
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b DIABETES : 2022
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-21
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-21
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-21
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-21
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b DIABETES : 2022
|d 2023-10-21
920 1 _ |0 I:(DE-He78)B350-20160331
|k B350
|l Metabolischer Crosstalk bei Krebserkrankungen
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)W120-20160331
|k W120
|l Proteomics
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B350-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)W120-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21